ERBB2 and breast carcinoma: In addition, many trials did not utilize the updated 2018 ASCO (American Society of Clinical Oncology)/CAP (College of American Pathologists) guidelines on HER2 interpretation in breast cancer [6], which generated an increase in negative cases due to the more rigorous algorithm for identifying HER2+ patients.